Literature DB >> 25675313

Evolution of the reliability of the fully implantable middle ear transducer over successive generations.

Mathilde Debeaupte1, Evelyne Decullier, Stephane Tringali, Arnaud Devèze, Thierry Mom, Vincent Darrouzet, Eric Truy.   

Abstract

OBJECTIVE: To describe the reliability of the fully implantable middle ear transducer after successive technological changes. STUDY
DESIGN: Prospective, observational, multicenter study.
SETTING: Eight tertiary referral centers. PATIENTS: One hundred twenty-three adults were implanted with one of the five successive versions of the fully implantable middle ear implant between September 2005 and July 2012.
METHODS: The reliability of each generation 2 years after implantation or at the maximal lifetime was reported by means of survival curves. Only technological failures were considered; non-technological failures were excluded from the analysis of reliability.
RESULTS: One hundred fifty-seven devices were implanted during the period of study. Fifteen explantations were related to non-technological problems (e.g., infections, extrusions, etc.). One hundred forty-two implants were followed in the analysis of reliability. We observed 32 technical failures at 2 years. At the maximal lifetime of follow-up, 46 implants failed. The end of the follow-up was the first of November 2012. Survival rates at 2 years were 0%, 76.1%, 84.2%, 81.8%, and 100% for each of the successive available versions, respectively.
CONCLUSION: The reliability of the fully implantable middle ear implant improved over generations thanks to successive technological modifications that corrected the observed failures. The latest generation seems to be a reliable fully implantable middle ear implant system up to 22 months after implantation. The need to know the reliability of these active middle ear implants incites the creation of a follow-up register including patient's data and device failures to improve patient management.

Entities:  

Mesh:

Year:  2015        PMID: 25675313     DOI: 10.1097/MAO.0000000000000718

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  7 in total

1.  The first results of a totally implanted active middle ear device.

Authors:  Maria da Conceição Peixoto; Cristina Miranda; Mafalda Bento; Susana Oliveira; Rui Pratas; Victor Correia da Silva
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-24       Impact factor: 2.503

2.  A Retrospective Multicentre Cohort Review of Patient Characteristics and Surgical Aspects versus the Long-Term Outcomes for Recipients of a Fully Implantable Active Middle Ear Implant.

Authors:  Philippe P Lefebvre; Javier Gisbert; Domenico Cuda; Stéphane Tringali; Arnaud Deveze
Journal:  Audiol Neurootol       Date:  2017-01-05       Impact factor: 1.854

3.  The Carina© middle ear implant: surgical and functional outcomes.

Authors:  Luca Bruschini; Stefano Berrettini; Francesca Forli; Alessandra Murri; Domenico Cuda
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-23       Impact factor: 2.503

4.  A New Trans-Tympanic Microphone Approach for Fully Implantable Hearing Devices.

Authors:  Seong Tak Woo; Dong Ho Shin; Hyung-Gyu Lim; Ki-Woong Seong; Peter Gottlieb; Sunil Puria; Kyu-Yup Lee; Jin-Ho Cho
Journal:  Sensors (Basel)       Date:  2015-09-09       Impact factor: 3.576

5.  Middle Ear Transducer: Long Term Stability of the Latest Generation T2.

Authors:  Nils Kristian Prenzler; Eugen Kludt; Thomas Giere; Rolf Salcher; Thomas Lenarz; Hannes Maier
Journal:  Biomed Res Int       Date:  2019-01-06       Impact factor: 3.411

6.  Battery Lifespan of an Implantable Middle Ear Device.

Authors:  Luca Bruschini; Francesca Forli; Giacomo Fiacchini; Rachele Canelli; Stefano Berrettini; Francesco Lazzerini
Journal:  Audiol Res       Date:  2022-09-07

7.  Packaging Technology for an Implantable Inner Ear MEMS Microphone.

Authors:  Lukas Prochazka; Alexander Huber; Ivo Dobrev; Francesca Harris; Adrian Dalbert; Christof Röösli; Dominik Obrist; Flurin Pfiffner
Journal:  Sensors (Basel)       Date:  2019-10-16       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.